Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.

MLA

Bellone, S., et al. “Downregulation of Membrane Complement Inhibitors CD55 and CD59 by SiRNA Sensitises Uterine Serous Carcinoma Overexpressing Her2/Neu to Complement and Antibody-Dependent Cell Cytotoxicity in Vitro: Implications for Trastuzumab-Based Immunotherapy.” British Journal of Cancer, vol. 106, no. 9, Apr. 2012, pp. 1543–50. EBSCOhost, https://doi.org/10.1038/bjc.2012.132.

APA

Bellone, S., Roque, D., Cocco, E., Gasparrini, S., Bortolomai, I., Buza, N., Abu-Khalaf, M., Silasi, D.-A., Ratner, E., Azodi, M., Schwartz, P. E., Rutherford, T. J., Pecorelli, S., & Santin, A. D. (2012). Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal of Cancer, 106(9), 1543–1550. https://doi.org/10.1038/bjc.2012.132

Chicago

Bellone, S, D Roque, E Cocco, S Gasparrini, I Bortolomai, N Buza, M Abu-Khalaf, et al. 2012. “Downregulation of Membrane Complement Inhibitors CD55 and CD59 by SiRNA Sensitises Uterine Serous Carcinoma Overexpressing Her2/Neu to Complement and Antibody-Dependent Cell Cytotoxicity in Vitro: Implications for Trastuzumab-Based Immunotherapy.” British Journal of Cancer 106 (9): 1543–50. doi:10.1038/bjc.2012.132.